About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

Follicular Lymphoma >  ASCO 2012 - Marginal Zone Lymphoma

Last update: 05/30/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL

Comments or Questions?

See also ASCO 2012 follicular lymphoma abstracts

 

1.        A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. |

 
2.      Survival with splenectomy in splenic marginal zone lymphoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. | 2012 ASCO Annual Meeting Abstracts

 
3.      Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

 
4.      Ocular adnexal lymphoma (OAL)-outcomes for 82 patients (pts) treated at a single center. |

 
5.      Prevalence of autoimmune conditions in patients with marginal zone lymphoma: Exploratory analysis of a series of consecutive patients.

 
6.      Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

 
7.    Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.

 
8.    LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL.

 
9.      Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).
 
10.  Geographic variation of extranodal sites of mucosal associated lymphoid tissue lymphoma (MALToma): Analysis of series from two institutions. | 2012 ASCO Annual Meeting Abstracts
 
11.  LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL.

 
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.